All In Biotech

Drug Trial Radar · NCT06624228

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 553 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

553

Actual

Start

Oct 21, 2024

Primary completion

Feb 6, 2026

Study completion Jun 3, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

Conditions

  • Psoriatic Arthritis

Interventions

  • BimekizumabDrug

    Study participants will receive bimekizumab at pre-specified time points.

  • RisankizumabDrug

    Study participants will receive risankizumab at pre-specified time points.

  • PlaceboDrug

    Study participants will receive placebo at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology 50 (ACR50) at Week 16Time frame: Week 16

Locations

127 sites in 11 countries. Site status is shown where the registry gives one.

  • Pa0016 50662

    Gilbert, Arizona

  • Pa0016 50062

    Glendale, Arizona

  • Pa0016 50058

    Phoenix, Arizona

  • Pa0016 50131

    Sun City, Arizona

  • Pa0016 50654

    Covina, California

  • Pa0016 50663

    San Diego, California

  • Pa0016 50672

    Santa Monica, California

  • Pa0016 50630

    Clearwater, Florida

  • Pa0016 50679

    Cutler Bay, Florida

  • Pa0016 50685

    Fort Lauderdale, Florida

  • Pa0016 50059

    Ormond Beach, Florida

  • Pa0016 50324

    Plantation, Florida

  • Pa0016 50678

    Zephyrhills, Florida

  • Pa0016 50651

    Skokie, Illinois

  • Pa0016 50650

    Willowbrook, Illinois

  • Pa0016 50686

    Hagerstown, Maryland

  • Pa0016 50665

    Lansing, Michigan

  • Pa0016 50551

    Saint Clair Shores, Michigan

  • Pa0016 50689

    Eagan, Minnesota

  • Pa0016 50682

    Kansas City, Missouri

  • Pa0016 50016

    St Louis, Missouri

  • Pa0016 50653

    Albuquerque, New Mexico

  • Pa0016 50666

    Brooklyn, New York

  • Pa0016 50664

    Middletown, Ohio

  • Pa0016 50680

    Vandalia, Ohio

  • Pa0016 50652

    Duncansville, Pennsylvania

  • Pa0016 50006

    Wyomissing, Pennsylvania

  • Pa0016 50001

    Jackson, Tennessee

  • Pa0016 50673

    Fort Worth, Texas

  • Pa0016 50048

    Katy, Texas

  • Pa0016 50657

    Lubbock, Texas

  • Pa0016 50655

    Tomball, Texas

  • Pa0016 50061

    Spokane Valley, Washington

  • Pa0016 50674

    Glendale, Wisconsin

  • Pa0016 30002

    Clayton, Australia

  • Pa0016 30034

    Footscray, Australia

  • Pa0016 30033

    Heidelberg, Australia

  • Pa0016 30003

    Maroochydore, Australia

  • Pa0016 30032

    Parramatta, Australia

  • Pa0016 30009

    Westmead, Australia

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.